Related Experiment Video
Updated: Aug 17, 2026

Morris Water Maze Experiment
Published on: September 24, 2008
Abstract:
The non-profit Cancer Research UK (CRUK) funds over £300 million worth of cancer research each year and, with the help of its development and commercialization arm Cancer Research Technology (CRT), has moved more than 30 partnered agents into preclinical and clinical development. Having established a small-molecule track record, CRUK now needs to build up more biologic know-how, says CRT Chief Executive Officer Keith Blundy. To this end, CRUK and AstraZeneca's antibody subsidiary, MedImmune, agreed in September to launch the joint CRUK-MEDI Alliance Laboratory. This fully collaborative and integrated partnership is a first of its kind, Blundy tells Asher Mullard.
Insights
Cancer Research UK is expanding its biologics expertise through a new alliance with MedImmune. This collaboration aims to advance cancer drug development by combining strengths in antibody research.
Area of Science:
- Oncology
- Biotechnology
- Pharmaceutical Development
Background:
- Cancer Research UK (CRUK) is a major funder of cancer research, investing over £300 million annually.
- Cancer Research Technology (CRT), CRUK's commercialization arm, has successfully advanced over 30 agents into development.
- CRUK seeks to enhance its capabilities in biologic drug development, complementing its existing small-molecule expertise.
Discussion:
- CRUK and MedImmune, AstraZeneca's antibody-focused subsidiary, have formed a novel joint laboratory, the CRUK-MEDI Alliance Laboratory.
- This partnership represents a new model for integrated, fully collaborative drug development in oncology.
- The alliance aims to leverage combined expertise to accelerate the discovery and development of novel cancer therapies.
Key Insights:
- CRUK is strategically expanding into biologics, specifically antibody-based therapeutics.
- The CRUK-MEDI Alliance Laboratory signifies a significant step in building CRUK's biologic know-how.
- This collaboration highlights a trend towards integrated partnerships in pharmaceutical R&D.
Outlook:
- The alliance is expected to accelerate the progression of biologic cancer agents into clinical trials.
- This initiative could serve as a blueprint for future collaborations between non-profit research organizations and pharmaceutical companies.
- The partnership aims to bring innovative biologic therapies to cancer patients more efficiently.
Related Concept Videos
Blind Procedures
Southern Blot
Denatured DNA fragments must be transferred onto a carrier membrane from the gel to make it accessible to a probe - a small ssDNA fragment complementary to the target DNA...
Blinding
Bending
In pure bending, the bending stress in a beam is calculated based on the bending moment and...
Bending of Material: Problem Solving
Unsymmetric Bending

